Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5232-5236

  Kreisberg, Jeffrey I ^a,c   Malik, Shazli N ^a   Prihoda, Thomas J ^a   Bedolla, Roble G ^a   Troyer, Dean A ^a   Kreisberg, Suzanne ^b   Ghosh, Paramita M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Immunosignal Transduction   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; SERINE; AKT1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER GRADING; HUMAN; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN PHOSPHORYLATION; ROC CURVE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; WILCOXON SIGNED RANKS TEST; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PREDICTION AND FORECASTING;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 3442891477     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0272     Document Type: Article

References (28)

1. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65.
2. Isaacs JT. Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst (Bethesda) 2000;92:1367-9.
3. American Cancer Society. Cancer Facts & Figures 2003. Atlanta, GA: American Cancer Society.
4. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (Bethesda) 2003;95:868-78.
5. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
6. Muggins C. Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Res 1965;25:1163-7.
7. Huggins C, Hodges CV. Studies on prostatic cancer. 1. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA-Cancer J Clin 1972;22:232-40.
8. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999;19:5143-54.
9. Prins GS, Sklarew RJ, Pertschuk LP. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 1998;159:641-9.
10. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-71.
11. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20:1981-9.
12. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
13. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (Bethesda) 1993;85:200-6.
14. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edition. New York: Wiley; 2000.
15. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2-11.
16. Freeman VL, Coard KC, Wojcik E, Durazo-Arvizu R. Use of the Gleason system in international comparisons of prostatic adenocarcinomas in blacks. Prostate 2004;58:169-73.
17. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-7.
18. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-5.
19. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001;142:4795-805.
20. Sun M, Wang G, Paciga JE, et al. AKT/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-7.
21. Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI. RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Cancer Res 2002;62:2630-6.
22. Price DT, Rocca GD, Guo C, et al. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999;162:1537-42.
23. Kim J, Adam RM, Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 2002;62:1549-54.
24. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999;253:210-29.
25. Thakkar H, Chen X, Tyan F, et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells: relationship with trail resistance. J Biol Chem 2001;276:38361-9.
26. Kops GJ, de Ruiter ND, De Vries-Smits AM, et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature (Lond) 1999;398:630-4.
27. Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999;274:16741-6.
28. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature (Lond) 2000;404:782-7.